%A Huang,Chao H. %A Williamson,Stephen K. %A Neupane,Prakash %A Taylor,Sarah A. %A Allen,Ace %A Smart,Nora J. %A Uypeckcuat,Adelina M. %A Spencer,Sarah %A Wick,Jo %A Smith,Holly %A Van Veldhuizen,Peter J. %A Kelly,Karen %D 2016 %J Frontiers in Oncology %C %F %G English %K dalotuzumab,Non-squamous cell lung cancer,Metastatic,IGF-1R,pemetrexed,Treatment %Q %R 10.3389/fonc.2015.00301 %W %L %M %P %7 %8 2016-January-13 %9 Clinical Trial %+ Chao H. Huang,Kansas City Veterans Administration Medical Center,USA,chuang2@kumc.edu %+ Chao H. Huang,University of Kansas Cancer Center,USA,chuang2@kumc.edu %# %! Dalotuzumab in metastatic non-squamous lung cancer %* %< %T Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer %U https://www.frontiersin.org/articles/10.3389/fonc.2015.00301 %V 5 %0 JOURNAL ARTICLE %@ 2234-943X %X BackgroundInsulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation, and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets IGF-1R. Pemetrexed (P) has higher activity in non-squamous lung cancer (NSQL). We initiated a randomized phase II trial to test the combination of P and Cisplatin (C) ± D in NSQL.MethodsEligibility criteria were untreated NSQL stage IV, ECOG 0 or 1, measurable disease, adequate renal, hepatic and hematologic function, and no other intercurrent illness. P at 500 mg/m2 and C at 75 mg/m2 IV were given every 3 weeks. D was given at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle in the experimental group. The patients had a radiographic assessment after every two cycles and were treated for a maximum of six cycles if there was a response or stable disease. The primary objective of the study was to compare the clinical response rates of PC vs. PC + D.ResultsFrom 1/2009 to 2/2011, the study accrued 26 subjects: 16 male and 10 female, with a median age of 59; 14 were treated with PC and 12 were treated with PC + D. We observed two partial responses (PR), seven stable disease (SD), three progressive disease (PD), and two not evaluable (NE) in the PC arm. In comparison, for the PC + D arm, there were three PR, four SD, four PD, and one NE. The hematologic toxicity was similar in both groups. There was higher incidence of hyperglycemia in the experimental group; four cases with grade 3 and one case with grade 4.ConclusionPC + D had a similar response rate compared to PC, with a higher rate of hyperglycemia. Identification of responders using predictive markers would be key to continuing the study of D in NSQL.Trial RegistrationNCT00799240, clinicaltrials.gov